Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605

Figure 3

A composite transcription signature is induced by CD8-IGF1R over-expression and A-928605 treatment of the transformed cells A, Expression profile of 1860 Affymetrix probe sets that were differentially expressed between CD8-IGF1R and vector control cells and between CD8-IGF1R vehicle and A-928605-treated cells by at least 1.5-fold and with a 5% FDR. Three independent plates, each represented by a column on the heat map, were analyzed from the vehicle-treated vector control, A-928605-treated vector control, vehicle-treated CD8-IGF1R, A-928605-treated CD8-IGF1R cell groups. Genes exhibiting decreased expression in CD8-IGF1R relative to vector control cells represent classes I (579 transcripts) and II (162 transcripts). Class III (968) and IV (151) transcripts exhibited increased expression in CD8-IGF1R relative to vector control cells. B, Relative expression level of key class I and III genes for each treatment group relative to vehicle-treated vector control cells. All vehicle treated vector control cells have gene expression normalized to 1.

Back to article page